H.C. Wainwright analyst Raghuram Selvaraju upgraded Idorsia (IDRSF) to Buy from Neutral with a price target of CHF 6, up from CHF 2. The company’s guidance provided a pathway to profitability, driven by European and Canadian market uptake of its marketed anti-insomnia medication daridorexant, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDRSF: